Company Filing History:
Years Active: 2023
Title: Céline Laumont: Innovator in Tumor-Specific Antigen Identification
Introduction
Céline Laumont is a prominent inventor based in Victoria, Canada. She has made significant contributions to the field of cancer research, particularly in the identification of tumor-specific antigens. Her innovative work aims to enhance the understanding of how T cells can be utilized in tumor eradication.
Latest Patents
Céline Laumont holds a patent for a "Proteogenomic-based method for identifying tumor-specific antigens." This method focuses on the role of CD8 T cells, which are crucial in the elimination of tumor cells. The patent describes a proteogenomic approach that utilizes RNA-sequencing data from cancer and normal-matched samples to identify non-tolerogenic tumor-specific antigens. This innovative technique works independently of the sample's mutational load or complexity, making it a versatile tool in cancer research.
Career Highlights
Céline Laumont is affiliated with the Université de Montréal, where she continues her research and development in the field of immunology. Her work has garnered attention for its potential to improve cancer treatment outcomes through the identification of specific antigens that can be targeted by T cells.
Collaborations
Céline collaborates with notable colleagues such as Pierre Thibault and Sébastien Lemieux. Their combined expertise contributes to advancing research in tumor immunology and the development of innovative therapeutic strategies.
Conclusion
Céline Laumont's contributions to the field of cancer research through her innovative patent and collaborations highlight her role as a leading inventor in the identification of tumor-specific antigens. Her work has the potential to significantly impact cancer treatment and improve patient outcomes.